5-phenyl-pyrimidine derivatives
    3.
    发明授权
    5-phenyl-pyrimidine derivatives 失效
    5-苯基 - 嘧啶衍生物

    公开(公告)号:US06756380B1

    公开(公告)日:2004-06-29

    申请号:US09575789

    申请日:2000-05-22

    IPC分类号: C07D23932

    摘要: Compounds of the general formula are described: wherein R1 is hydrogen or halogen; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; R3 is halogen, trifluoromethyl, lower alkoxy or lower alkyl; R4/R4′are each independently hydrogen or lower alkyl; R5 is lower alkyl, lower alkoxy, amino, hydroxy, hydroxy-lower alkyl, —(CH2)n-piperazinyl, optionally substituted by lower alkyl, —(CH2)n-morpholinyl, —(CH2)n+1-imidazolyl, —O—(CH2)n+1-morpholinyl, —O—(CH2)n+1-piperidinyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, —NH—(CH2)n+1N(R4″)2, —(CH2)n—NH—(CH2)n+1N(R4″)2, —(CH2)n+1N(R4″)2, or —O—(CH2)n+1N(R4″)2, wherein R4″ is hydrogen or lower alkyl; R6 is hydrogen; R2 and R6 or R1 and R6 may together be —CH═CH—CH═CH—, wherein R2 and R6 or R1 and R6, respectively, together with the two carbon ring atoms to which they are attached form a fused ring, with the proviso that n for R1 is 1; n is independently 0-2; and X is —C(O)N(R4″)— or —N(R4″)C(O)—; and pharmaceutically acceptable acid addition salts thereof.

    摘要翻译: 描述通式的化合物:其中R 1是氢或卤素; R 2是氢,卤素,低级烷基或低级烷氧基; R 3是卤素,三氟甲基,低级烷氧基或低级烷基; R 4 R 5是氢或低级烷基; R 5是低级烷基,低级烷氧基,氨基,羟基,羟基 - 低级烷基, - (CH 2)n - 哌嗪基,任选被低级烷基取代, (CH2)n-吗啉基, - (CH2)n + 1-咪唑基,-O-(CH2)n + 1-吗啉基,-O-(CH2)n + 1-哌啶基,低级烷基 - ,苄基氨基,-NH-(CH 2)n + 1N(R 4“)2, - (CH 2)n -NH-(CH 2)n + 1N(R 4”)2, - (CH 2) n + 1N(R 4“)2或-O-(CH 2)n + 1N(R 4”)2,其中R 4“是氢或低级烷基; R 6' R 2和R 6或R 1和R 6可以一起为-CH = CH-CH = CH-,其中R 2和R 6或R 1为氢; 和R 6分别与它们所连接的两个碳环原子一起形成稠合环,条件是R 1的n为1; n独立地为0-2; 和X是-C(O)N(R“”) - 或-N(R“”)C(O) - ;及其药学上可接受的酸加成盐。

    Biphenyl derivatives
    7.
    发明授权
    Biphenyl derivatives 失效
    联苯衍生物

    公开(公告)号:US06291465B1

    公开(公告)日:2001-09-18

    申请号:US09513147

    申请日:2000-02-25

    IPC分类号: C07C23300

    摘要: The invention relates to compounds of the formula wherein R is hydrogen, lower alkyl, lower alkoxy halogen, amino, —N(R6)2 or trifluoromethyl; R1 is hydrogen lower alkoxy or halogen, R and R1 may be together —CH═CH—CH═CH—; R2 is halogen, lower alkyl or trifluoromethyl; R3 is hydrogen or lower alkyl; R4 is hydrogen or a cyclic tertiary amine, optionally substituted by lower alkyl; R5 is hydrogen, nitro, amino or —N(R6)2; R6 is hydrogen or lower alkyl, X is —C(O)N(R6)—, —(CH2)nO—, (CH2)nN(R6)—, —N(R6)C(O)— or —N(R6)(CH2)n—; and n is 1 or 2; and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I may be used for the treatment of diseases related to the NK-1 receptor.

    摘要翻译: 本发明涉及式的化合物,其中R是氢,低级烷基,低级烷氧基卤素,氨基,-N(R6)2或三氟甲基; R1是氢低级烷氧基或卤素,R和R1可以一起是-CH = CH-CH = CH-; R 2为卤素,低级烷基或三氟甲基; R 3为氢或低级烷基; R 4为氢或环状叔胺,任选被低级烷基取代; R 5为氢,硝基,氨基或-N(R 6) X是-C(O)N(R6) - , - (CH2)nO-,(CH2)nN(R6) - , - (R6)C(O) - 或-N )(CH 2)n - 和n为1或2;及其药学上可接受的酸加成盐。式I化合物可用于治疗与NK-1受体有关的疾病。